How long til we're all on Ozempic?

Clinical effects & risks

• Many commenters report significant weight loss and reduced “food noise” on GLP‑1 drugs (semaglutide/Ozempic, tirzepatide/Mounjaro/Zepbound), plus secondary benefits like improved focus, less anxiety, and lower cravings for alcohol, nicotine, cannabis, and junk food.
• Others note classic side effects: nausea, reflux, very small stomach capacity, GI slowing, occasional constipation, and concern about potential gastroparesis and bowel obstruction.
• Long‑term safety is debated. Some argue there are ~20 years of GLP‑1 data with no obvious large, delayed harms; others point to animal cancer signals, limited independent data, and historical examples (opioids, aspirin, wine, smoking) where risks emerged late.
• Concerns about loss of muscle mass and bone density are raised; replies say muscle loss accompanies any weight loss, and some data suggest GLP‑1s may improve bone density, but strength training is widely recommended.

Lifestyle vs. medication

• One camp stresses “eat less and exercise more,” intermittent fasting, keto/low‑carb, and environmental changes (walkable cities, better food policy) as root‑cause solutions.
• Another cites large cohort studies showing very low long‑term success rates for lifestyle‑only weight loss and strong biological “set‑point” effects; they frame obesity as a chronic metabolic disease where drugs are appropriate maintenance, like antihypertensives or insulin.
• Strong moral overtones appear: some view GLP‑1 use as eroding willpower or “cheating”; others push back, comparing this stance to shaming people for using antidepressants or ADHD meds.

Societal, behavioral, and cultural impacts

• Several argue obesity is mostly environmental: cheap ultra‑processed food, car‑centric life, long work hours, aggressive food marketing, especially to children.
• There’s speculation GLP‑1–driven appetite and impulse reduction could change consumption patterns far beyond food: less alcohol, less compulsive shopping, possibly lower overall hedonism – or, conversely, greater dependence on pharma to cope with a toxic environment.
• Some fear widespread use could delay or derail needed structural reforms to food systems and urban design.

Economics, access, and industry dynamics

• US out‑of‑pocket costs are described as “incredibly expensive”; insurance coverage is patchy and often requires prior authorization.
• Compounded semaglutide/tirzepatide and Chinese peptides are much cheaper but have regulatory and quality concerns.
• Manufacturing capacity is a bottleneck, especially for autoinjector devices rather than the peptide itself.
• Commenters expect huge long‑term markets, patent battles, and potential future cheap generics; some worry about drug makers shaping policy and suppressing lower‑cost competition.